PT  - JOURNAL ARTICLE
AU  - Samantha H. Chiang
AU  - Michael Tu
AU  - Jordan Cheng
AU  - Fang Wei
AU  - Feng Li
AU  - David Chia
AU  - Omai Garner
AU  - Sukantha Chandrasekaran
AU  - Richard Bender
AU  - Charles M. Strom
AU  - David T.W. Wong
TI  - Development and validation of a highly sensitive and specific electrochemical assay to quantify anti-SARS-CoV-2 IgG antibodies to facilitate pandemic surveillance and monitoring of vaccine response
AID  - 10.1101/2020.11.12.20230656
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.11.12.20230656
4099  - http://medrxiv.org/content/early/2020/11/16/2020.11.12.20230656.short
4100  - http://medrxiv.org/content/early/2020/11/16/2020.11.12.20230656.full
AB  - Amperial™ is a novel assay platform that uses immobilized antigen in a conductive polymer gel followed by an electrochemical detection. A highly specific and sensitive assay was developed to quantify levels of IgG antibodies to SARS-CoV-2 in saliva. After establishing linearity and limit of detection we established a reference range of 5 standard deviations above the mean. There were no false positives in 667 consecutive saliva samples obtained prior to 2019. Saliva was obtained from 34 patients who had recovered from documented COVID-19 or had documented positive serologies. All of the patients with symptoms severe enough to seek medical attention had positive antibody tests and 88% overall had positive results.We obtained blinded paired saliva and plasma samples from 14 individuals. The plasma was analyzed using an EUA-FDA cleared ELISA kit and the saliva was analyzed by our Amperial™ assay. All 5 samples with negative plasma titers were negative in saliva testing. Eight of the 9 positive plasma samples were positive in saliva and 1 had borderline results. A CLIA validation was performed as a laboratory developed test in a high complexity laboratory.A quantitative non-invasive saliva based SARSCoV-2 antibody test was developed and validated with sufficient specificity to be useful for population-based monitoring and monitoring of individuals following vaccination.Competing Interest StatementCS is a founder and CEO of Liquid Diagnostics, LLC and holds equity in the company. MT is an employee and an equity holder in Liquid Diagnostics. RB is the CMO of Liquid Diagnostics and holds equity in the company. DW is and equity holder in Liquid Diagnostics, LLC. He is a consultant to Mars Wrigley and Colgate-PalmoliveFunding StatementDW is supported by U54HL119893, UCLA W.M. Keck Foundation Research Award Program. SC is supported by F30DE027615.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UCLA IRB #06-05-042All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data will be available as requested